β受体阻断剂市场－全球产业规模、份额、趋势、机会和预测，按类型、适应症、药物、配销通路、应用、地区和竞争格局划分，2020-2030年预测

2024年全球β受体阻断剂市场规模为99.4亿美元，预计2030年将以5.95%的复合年增长率成长至140.6亿美元。 β受体阻断剂是一类药物，其作用机转是透过抑制肾上腺素（也称为肾上腺素）对心臟和血管的影响。这种作用可降低心率和心肌收缩力，进而降低血压并改善血流。全球β受体阻断剂市场的主要驱动因素是心血管疾病（包括高血压、心绞痛和心律不整）盛行率的上升，以及老年人口的不断增长，而老年人本身就更容易患上这些疾病。

主要市场驱动因素

心血管疾病负担日益加重是全球β受体阻断剂市场的主要驱动因素。这些疾病包括高血压、心绞痛和各种心律不整，需要采取治疗介入措施来控制症状和预防疾病进展。

主要市场挑战

主要品牌β受体阻断剂专利到期对全球市场成长构成重大挑战。专利保护期结束后，仿製药生产商会推出生物等效版本，加剧价格竞争，并导致市场饱和。

主要市场趋势

全球β受体阻断剂市场受到药物递送系统不断改进和治疗效果提升的显着影响。这一趋势涵盖了新型製剂和新一代药物，旨在透过优化药物动力学和减少副作用来改善患者疗效。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球β受体阻断剂市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型（非选择性试剂、选择性试剂）
  • 依适应症（心绞痛、心臟衰竭、高血压、其他）
  • 依药物分类（倍他洛尔、醋丁洛尔、艾司洛尔、其他）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 依应用领域（心臟病、高血压、青光眼、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美β受体阻断剂市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲β受体阻断剂市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区β受体阻断剂市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲β受体阻断剂市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲β受体阻断剂市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球β受体阻断剂市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Pfizer Inc
• Novartis AG
• Merck & Co. Inc
• AstraZeneca PLC
• Johnson and Johnson Services, Inc.
• Eli Lilly and Company
• Sanofi SA
• Bristol-Myers Squibb
• Bayer AG
• GlaxoSmithKline plc

第十六章：策略建议

第17章调查会社について・免责事项

The Global Beta blockers Market, valued at USD 9.94 Billion in 2024, is projected to experience a CAGR of 5.95% to reach USD 14.06 Billion by 2030. Beta blockers represent a class of pharmaceutical agents that function by inhibiting the effects of epinephrine, also known as adrenaline, on the heart and blood vessels. This action results in a reduced heart rate and decreased force of cardiac contraction, thereby lowering blood pressure and enhancing blood flow. The global market for beta blockers is primarily driven by the rising prevalence of cardiovascular diseases, including hypertension, angina, and arrhythmias, coupled with an expanding geriatric population that is inherently more susceptible to such conditions.

Key Market Drivers

The increasing burden of cardiovascular diseases represents a fundamental driver for the global beta blockers market. These conditions, encompassing hypertension, angina, and various arrhythmias, necessitate therapeutic interventions to manage symptoms and prevent disease progression. The continued rise in these diagnoses directly expands the patient pool requiring cardiac medications.

Key Market Challenges

The impact of patent expirations on key brand-name beta blockers poses a significant challenge to the growth of the global market. Upon the loss of patent exclusivity, generic manufacturers introduce bioequivalent versions, intensifying price competition and increasing market saturation. This dynamic typically results in a substantial decline in revenue for originator companies as market share shifts towards these lower-priced generic alternatives.

Key Market Trends

The global beta blockers market is significantly influenced by the continuous development of more sophisticated drug delivery systems and enhanced therapeutic profiles. This trend, encompassing both novel formulations and next-generation agents, aims to improve patient outcomes through optimized pharmacokinetics and reduced side effects. For instance, the United States Pharmacopeia announced on August 30, 2024, that four new dissolution tests were added to the Metoprolol Succinate Extended-Release Tablets monograph, reflecting ongoing FDA approvals of diverse extended-release formulations.

Key Market Players

• Pfizer Inc
• Novartis AG
• Merck & Co. Inc
• AstraZeneca PLC
• Johnson and Johnson Services, Inc.
• Eli Lilly and Company
• Sanofi SA
• Bristol-Myers Squibb
• Bayer AG
• GlaxoSmithKline plc

Report Scope:

In this report, the Global Beta blockers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Beta blockers Market, By Type:

• Non-selective Agents
• Selective Agents

Beta blockers Market, By Indications:

• Angina Pectoris
• Heart Failure
• High Blood Pressure
• Others

Beta blockers Market, By Drugs:

• Betaxolol
• Acebutolol
• Esmolol
• Others

Beta blockers Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Beta blockers Market, By Application:

• Cardiac Diseases
• Hypertension
• Glaucoma
• Others

Beta blockers Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Beta blockers Market.

Available Customizations:

Global Beta blockers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Beta blockers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Non-selective Agents, Selective Agents)
  • 5.2.2. By Indications (Angina Pectoris, Heart Failure, High Blood Pressure, Others)
  • 5.2.3. By Drugs (Betaxolol, Acebutolol, Esmolol, Others)
  • 5.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.5. By Application (Cardiac Diseases, Hypertension, Glaucoma, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Beta blockers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Indications
  • 6.2.3. By Drugs
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Application
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Beta blockers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Indications
      • 6.3.1.2.3. By Drugs
      • 6.3.1.2.4. By Distribution Channel
      • 6.3.1.2.5. By Application
  • 6.3.2. Canada Beta blockers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Indications
      • 6.3.2.2.3. By Drugs
      • 6.3.2.2.4. By Distribution Channel
      • 6.3.2.2.5. By Application
  • 6.3.3. Mexico Beta blockers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Indications
      • 6.3.3.2.3. By Drugs
      • 6.3.3.2.4. By Distribution Channel
      • 6.3.3.2.5. By Application

7. Europe Beta blockers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Indications
  • 7.2.3. By Drugs
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Application
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Beta blockers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Indications
      • 7.3.1.2.3. By Drugs
      • 7.3.1.2.4. By Distribution Channel
      • 7.3.1.2.5. By Application
  • 7.3.2. France Beta blockers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Indications
      • 7.3.2.2.3. By Drugs
      • 7.3.2.2.4. By Distribution Channel
      • 7.3.2.2.5. By Application
  • 7.3.3. United Kingdom Beta blockers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Indications
      • 7.3.3.2.3. By Drugs
      • 7.3.3.2.4. By Distribution Channel
      • 7.3.3.2.5. By Application
  • 7.3.4. Italy Beta blockers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Indications
      • 7.3.4.2.3. By Drugs
      • 7.3.4.2.4. By Distribution Channel
      • 7.3.4.2.5. By Application
  • 7.3.5. Spain Beta blockers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Indications
      • 7.3.5.2.3. By Drugs
      • 7.3.5.2.4. By Distribution Channel
      • 7.3.5.2.5. By Application

8. Asia Pacific Beta blockers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Indications
  • 8.2.3. By Drugs
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Application
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Beta blockers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Indications
      • 8.3.1.2.3. By Drugs
      • 8.3.1.2.4. By Distribution Channel
      • 8.3.1.2.5. By Application
  • 8.3.2. India Beta blockers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Indications
      • 8.3.2.2.3. By Drugs
      • 8.3.2.2.4. By Distribution Channel
      • 8.3.2.2.5. By Application
  • 8.3.3. Japan Beta blockers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Indications
      • 8.3.3.2.3. By Drugs
      • 8.3.3.2.4. By Distribution Channel
      • 8.3.3.2.5. By Application
  • 8.3.4. South Korea Beta blockers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Indications
      • 8.3.4.2.3. By Drugs
      • 8.3.4.2.4. By Distribution Channel
      • 8.3.4.2.5. By Application
  • 8.3.5. Australia Beta blockers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Indications
      • 8.3.5.2.3. By Drugs
      • 8.3.5.2.4. By Distribution Channel
      • 8.3.5.2.5. By Application

9. Middle East & Africa Beta blockers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Indications
  • 9.2.3. By Drugs
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Application
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Beta blockers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Indications
      • 9.3.1.2.3. By Drugs
      • 9.3.1.2.4. By Distribution Channel
      • 9.3.1.2.5. By Application
  • 9.3.2. UAE Beta blockers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Indications
      • 9.3.2.2.3. By Drugs
      • 9.3.2.2.4. By Distribution Channel
      • 9.3.2.2.5. By Application
  • 9.3.3. South Africa Beta blockers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Indications
      • 9.3.3.2.3. By Drugs
      • 9.3.3.2.4. By Distribution Channel
      • 9.3.3.2.5. By Application

10. South America Beta blockers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Indications
  • 10.2.3. By Drugs
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Application
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Beta blockers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Indications
      • 10.3.1.2.3. By Drugs
      • 10.3.1.2.4. By Distribution Channel
      • 10.3.1.2.5. By Application
  • 10.3.2. Colombia Beta blockers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Indications
      • 10.3.2.2.3. By Drugs
      • 10.3.2.2.4. By Distribution Channel
      • 10.3.2.2.5. By Application
  • 10.3.3. Argentina Beta blockers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Indications
      • 10.3.3.2.3. By Drugs
      • 10.3.3.2.4. By Distribution Channel
      • 10.3.3.2.5. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Beta blockers Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Merck & Co. Inc
• 15.4. AstraZeneca PLC
• 15.5. Johnson and Johnson Services, Inc.
• 15.6. Eli Lilly and Company
• 15.7. Sanofi SA
• 15.8. Bristol-Myers Squibb
• 15.9. Bayer AG
• 15.10. GlaxoSmithKline plc

16. Strategic Recommendations

17. About Us & Disclaimer